Herceptin® (trastuzumab) in HER2-positive early breast cancer: protocol for a systematic review and cumulative network meta-analysis.

about

Herceptin® (trastuzumab) in HER2-positive early breast cancer: protocol for a systematic review and cumulative network meta-analysis.

Item

http://www.wikidata.org/entity/Q42374085

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Herceptin® (trastuzumab) in HE ...... ulative network meta-analysis.

@en

type

Item

label

Herceptin® (trastuzumab) in HE ...... ulative network meta-analysis.

@en

prefLabel

Herceptin® (trastuzumab) in HE ...... ulative network meta-analysis.

@en

P1476

Herceptin® (trastuzumab) in HE ...... mulative network meta-analysis

@en

P2093

Chris Cameron

http://www.w3.org/2001/XMLSchema#string

Christine Brezden-Masley

http://www.w3.org/2001/XMLSchema#string

Mariya Yurchenko

http://www.w3.org/2001/XMLSchema#string

Megan E Coombes

http://www.w3.org/2001/XMLSchema#string

Quinlan Wylie

http://www.w3.org/2001/XMLSchema#string

P2860

Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement

First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

Incorporating data from various trial designs into a mixed treatment comparison model.

Missing data and measurement variability in assessing progression-free survival endpoint in randomized clinical trials.

The importance of adjusting for potential confounders in Bayesian hierarchical models synthesising evidence from randomised and non-randomised studies: an application comparing treatments for abdominal aortic aneurysms

P2888

s13643-017-0588-2

P304

196

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13643-017-0588-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Becky Skidmore

Brian Hutton

Florence R Wilson

P577

2017-10-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1092156253

http://www.w3.org/2001/XMLSchema#string

P698

29017563

http://www.w3.org/2001/XMLSchema#string

P932

5634826

http://www.w3.org/2001/XMLSchema#string